Fulcrum Therapeutics

FDA Halts Fulcrum Trial, the Latest Setback in a Week of Sickle Cell Stumbles

Fulcrum Therapeutics offered few details about the clinical hold the FDA placed on its Phase 1b test of its sickle cell disease drug. Graphite Bio, Intellia Therapeutics, and Sangamo Therapeutics also encountered setbacks to their sickle cell programs.

By Frank Vinluan

Pharma, Startups

Fulcrum Therapeutics raises $80M to develop muscular dystrophy drug

Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.

By Alaric DeArment